Despite all restrictions and taking into account the COVID regulations, CEO Dr. Bolzern did not miss the opportunity to attend the celebration of the 25th anniversary of the PharmaZell Group site Chennai (India).
We are pleased to announce that the activities on synthetic CBD at our Farmabios site are progressing smoothly. The API is produced at a commercial batch size using a THC-free route, allowing us to satisfy high customer demands. As extension to the existing EU- and US-DMF for our pharmaceutical grade CBD, a Novel Food dossier
In October 2020 our new investor Bridgepoint visited the Farmabios site in Gropello-Cairolli (Italy). Besides holding its regular board meeting, the attendees went on an extensive plant tour. They were impressed by its capabilities, the in-depth know-how of its employees and the rapid progress of the new steroid building construction. The latter is going to
PharmaZell Group is very conscious of our important role and duty in delivering APIs to our customers and being an active part in maintaining the health system running. Up to now, the PharmaZell Group has been able to limit the impact of the Corona Virus outbreak (COVID-19) to the largest extent. Despite the fact that
During this critical and challenging period, Farmabios SpA states that our activities are regularly proceeding. We are conscious of the role and duty in delivering APIs, and our active part in the health system. We are doing our utmost to preserve our partners’ service continuously through our the work of our head quarter and manufacturing
As part of an ongoing investment program to enhance PharmaZell Group’s production output, we have initiated the construction of a brand new large steroid building and a new warehouse on the Farmabios premises in Gropello Cairoli (Italy). Construction work began in Dec 2019, a symbolic ground breaking ceremony is planned for Mar 2020. The investment
We are very glad to announce that the competent Italian authority (AIFA) has issued a renewed GMP certificate for our Farmabios SpA production facility [http://eudragmdp.ema.europa.eu/inspections/gmpc/generateGMPCPDF.do].
Global API supplier Farmabios announced today the addition of an ultra-pure synthetic Cannabidiol (CBD) drug substance to its portfolio. With an EU Drug Master File and cGMP manufacturing capacities, Farmabios is now positioned to fulfill a secure and scalable supply of CBD, from clinical needs to full-scale commercial operations. “As a long-standing supplier of specialized